A Clinical Study Of MpMRI/mpUS Cognitive Fusion Guided Transrectal Biopsy In Diagnosis Of Prostate Cancer

objective:In this project,we compare the detection rate of the mpMRI/mpUS cognitive fusion guided transrectal biopsy with the systematic transrectal ultrasonography biopsy,intending to explore the clinical value of mpMRI/mpUS cognitive fusion guided transrectal biopsy in the diagnosis of prostate cancer.Methods: A total of 137 patients with suspected prostate cancer in the Second Xiangya Hospital of Central South University from January2020 to January 2022 were collected.Among them seventy-one patients underwent systematic 12-core transrectal ultrasonography biopsy,and the remaining 66 patients underwent systematic 12-core transrectal ultrasonography biopsy and additionally mpMRI/mpUS cognitive fusion guided transrectal biopsy.The accordance rate of mp MRI and mp US in diagnosing prostate cancer was compared based on pathological results.comparing the detection rate of prostate cancer,clinically significant prostate cancer and the positive rate of single core between cognitive fusion biopsy group and systematic biopsy group,as well as the detection rate of prostate cancer and clinical significant prostate cancer between targeted biopsy and systematic biopsy in cognitive fusion biopsy group.Besides,we also focused on the incidence of postoperative complications between the two biopsy methods,ultimately verified the role of mpMRI/mpUS cognitive fusion guided transrectal prostate targeted biopsy in the diagnosis of prostate cancer.Results: There were no statistical differences in age,height,weight,BMI,t PSA,prostate volume and PSAD between the two groups.The positive rate of PSA in the range of 4-10ng/ml,10-20ng/ml,20-50ng/ml and >50ng/ml between the two groups were(16.67% vs 20%),(29.41%vs 11.76%),(66.67% vs 36.84%),(94.44% vs 83.33%),respectively.In the PSA range of 4-10ng/ml and 10-20ng/ml,there was no statistical difference between the positive rate of PSAD≥0.15 and PSAD < 0.15(13.33% vs 11.11%),(16.13% vs 33.33%),respectively.The sensitivity,specificity and diagnose accordance rate of mpMRI/mpUS fusion in detecting prostate cancer were higher than those of any of the methods.The detection rates of Pca and cs Pca of TB were higher than those of SB in TB+SB group(56.06% vs 38.03%),(53.03% vs 30.99%),respectively.and the differences were statistically significant.The single core positive rate of prostate cancer and clinically significant prostate cancer in TB+SB group were higher than those in SB group(40.06% vs 26.41%,31.69 vs23.94),and the differences were statistically significant.The single core positive rate of TB method in prostate cancer and clinically significant prostate cancer were higher than that in SB method in cognitive fusion biopsy group(51.22% vs 37.75%,39.63% vs 30.05),the difference was statistically significant.The incidence of complications such as blood stool,hematuria and fever after biopsy presented no difference in above two groups.Conclusion: mpMRI/mpUS cognitive fusion guided transrectal biopsy can achieve a batter detection rate to systematic biopsy with fewer core,but targeted biopsy cannot completely replace systematic biopsy.mpMRI/mpUS cognitive fusion guided transrectal biopsy combined with systematic biopsy is a better choice.